Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older

Tahapan Penelitian : Complete
Sponsor:
Mitra Pelaksana:
PT Tigermed Consulting Indonesia
No Registry
INA-P0HETP2
Tanggal Input Registry : 19-07-2024

01-01-2021
not specified
 
Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older
Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older
Interventional
SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine
5
 

Inclusion Criteria:

not specified

Exclusion Criteria:

not specified
 
not specified
Not applicable
PPUK/PPUB number
not specified